Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 5,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now owns 33,611 shares of the company's stock, valued at $1,972,629.59. The trade was a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Price Performance

HALO traded up $0.83 on Friday, reaching $60.98. The company had a trading volume of 1,491,680 shares, compared to its average volume of 1,304,861. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a market cap of $7.51 billion, a price-to-earnings ratio of 17.78, a P/E/G ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The business has a 50 day simple moving average of $55.44 and a 200 day simple moving average of $54.78.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Benchmark reaffirmed a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $62.78.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently added to or reduced their stakes in the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter worth approximately $29,000. Smartleaf Asset Management LLC grew its position in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.